RT Journal Article SR Electronic T1 Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry JF medRxiv FD Cold Spring Harbor Laboratory Press SP 19001032 DO 10.1101/19001032 A1 Tennen, Ruth I. A1 Laskey, Sarah B. A1 Koelsch, Bertram L. A1 McIntyre, Matthew H. A1 The 23andMe Health Team A1 Tung, Joyce Y. YR 2019 UL http://medrxiv.org/content/early/2019/08/09/19001032.abstract AB Current guidelines recommend BRCA1 and BRCA2 genetic testing for individuals with a personal or family history of certain cancers. Three BRCA1/2 founder variants — 185delAG (c.68_69delAG), 5382insC (c.5266dupC), and 6174delT (c.5946delT) — are common in the Ashkenazi Jewish population. We characterized a cohort of more than 2,800 research participants in the 23andMe database who carry one or more of the three Ashkenazi Jewish founder variants, evaluating two characteristics that are typically used to recommend individuals for BRCA testing: self-reported Jewish ancestry and family history of breast, ovarian, prostate, or pancreatic cancer. Of the 1,967 carriers who provided self-reported ancestry information, 21% did not self-report any Jewish ancestry; of these individuals, more than half (62%) do have detectable Ashkenazi Jewish genetic ancestry. In addition, of the 343 carriers who provided both ancestry and family history information, 44% did not have a first-degree family history of a BRCA-related cancer and, in the absence of a personal history of cancer, would therefore be unlikely to qualify for clinical genetic testing. These findings provide support for the growing call for broader access to BRCA genetic testing.Competing Interest StatementR.I.T., S.B.L., B.L.K, M.H.M., J.Y.T., and members of The 23andMe Health Team are current or former employees of and have stock, stock options, or both, in 23andMe, Inc.Funding StatementNo external funding was received for this study.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in the manuscript.